Institut Jantung Negara (IJN) has achieved a regional milestone by becoming the first centre in Southeast Asia to successfully implant the AVEIR™ DR, the world’s first dual-chamber leadless pacemaker system, developed by Abbott.
Approved by the U.S. Food and Drug Administration (FDA) in June 2023, the AVEIR™ DR system represents a breakthrough in cardiac pacing technology. Unlike traditional pacemakers, which require wires (leads) and a surgical pocket under the skin, this innovative system uses two miniaturised pacemakers, each about one-tenth the size of a conventional device implanted directly into the right atrium and right ventricle of the heart.
“IJN continues to set new standards for heart care in Malaysia and the region,” said Dr. Azlan, Senior Consultant Cardiologist and Clinical Director for Interventional Electrophysiology and Implantable Devices at IJN. “This groundbreaking technology significantly reduces complications such as infections, lead dislodgement, or vessel occlusion, while improving the quality of life for patients with abnormal heart rhythms.”
At the core of the AVEIR™ DR system is Abbott’s proprietary i2i™ (implant-to-implant) communication technology, which enables wireless, real-time coordination between the two pacemakers using high-frequency pulses conducted through the body's natural blood flow. This allows for more natural heart rhythm synchronisation and enhances device longevity by consuming less power compared to traditional wireless methods like Bluetooth® or radio-frequency signals.
“This innovation opens up new possibilities for safer and more effective cardiac care,” Dr. Azlan added.
The system also provides real-time pacing analysis, allowing doctors to verify device placement before completing the procedure. This feature, along with its leadless design, makes it a promising solution for patients suffering from bradycardia, a condition where the heart beats too slowly.
At IJN, innovation is not just about new technology, it's about creating real impact. The A VEIR™ DR implantation marks a leap forward in heart care, reinforcing our role as a regional leader. As cardiovascular disease remains a national challenge, we believe awareness, early intervention, and cutting-edge solutions must go hand in hand." said Chief Executive Officer of IJN, Prof. Dato' Sri Dr. Mohamed Ezani Md Taib
